Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Am J Dermatopathol ; 39(12): 907-909, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29095740

RESUMEN

Melanocytic matricoma is a recently described cutaneous adnexal tumor composed of matrical and supramatrical cells admixed with pigmented dendritic melanocytes, thought to recapitulate the anagen bulb of the hair follicle. We report a case of a 75-year-old white man, which demonstrates consumption of the epidermis that is defined as thinning of the epidermis with attenuation of the basal and suprabasal layers and loss of the normal rete architecture in areas of direct contact with neoplastic cells. It has been associated with aggressive histologic features in melanoma and likely represents an early phase of ulceration due to attenuation. Epidermal consumption has not been previously reported in nonmelanocytic tumors and it is uncertain whether this atypical histologic feature represents a sign of malignant behavior in this rare tumor.


Asunto(s)
Enfermedades del Cabello/patología , Melanocitos/patología , Neoplasias de Anexos y Apéndices de Piel/patología , Neoplasias Cutáneas/patología , Anciano , Humanos , Masculino
3.
Dermatol Online J ; 22(6)2016 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-27617611

RESUMEN

Posttransplantation lymphoproliferative disorder (PTLD) is a rare complication of solid organ or allogenic bone marrow transplantation. Cases localized to the skin are even rarer, with only around 100 cases recorded in the literature [2]. We present a case of 60 year-old-woman, a lung transplant recipient, who presented with an asymptomatic violaceous nodule on her left medial calf. Histopathology was consistent with PTLD of the B-cell subtype, EBV negative. This case is unique in that it was of the B cell subtype of cutaneous PTLD, which has been less commonly observed than the T cell subtype. In addition, the case was EBV negative, which is rare in B cell cutaneous PTLD. The patient was treated with rituximab 600 mg IV weekly for four weeks and cytomegalovirus immune globulin (Cytogam) 100 mg/kg once, with resolution of the nodule.


Asunto(s)
Rechazo de Injerto/prevención & control , Inmunosupresores/efectos adversos , Trasplante de Pulmón , Linfoma de Células B Grandes Difuso/etiología , Recurrencia Local de Neoplasia/etiología , Neoplasias Cutáneas/etiología , Antineoplásicos/uso terapéutico , Femenino , Humanos , Huésped Inmunocomprometido , Pierna , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/inmunología , Linfoma de Células B Grandes Difuso/patología , Persona de Mediana Edad , Recurrencia Local de Neoplasia/inmunología , Recurrencia Local de Neoplasia/patología , Enfermedad Pulmonar Obstructiva Crónica/cirugía , Rituximab/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA